
FRESENIUS MEDICAL CARE-ADR
FMSNYSETrading Snapshot
- Day Range
- $23.47 β $24.00
- 52-Week Range
- $20.02 β $27.64
- Volume
- $2.43B
- Avg Volume
- $2.26B
- Shares Outstanding
- 537.1M
- Next Earnings
- Sep 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $19.63B
- Last Q Revenue
- $4.86B
- P/E Ratio
- 12.4
- P/S Ratio
- 0.6x
- EPS (TTM)
- $1.75
- Dividend Yield
- 3.63%
Why Investors Own FMS
- βHigh-growth profile β revenue up -7.6% YoY with expanding US Equity exposure.
- βHealthy economics β 58% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About FRESENIUS MEDICAL CARE-ADR
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

Fresenius Medical Care AG 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Fresenius Medical Care AG in conjunction with their 2026 Q2 earnings call.
Bernstein Maintains Market Perform on Fresenius Medical Care, Raises Price Target to $25.8
Bernstein analyst Lisa Clive maintains Fresenius Medical Care (NYSE:FMS) with a Market Perform and raises the price target from $25.5 to $25.8.

Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call August 4, 2026 4:00 AM EDTCompany ParticipantsDominik Heger - Executive VP and Head of Investor...

Fresenius Medical Care Q2 2026 Earnings Call Transcript
Fresenius Medical Care (NYSE:FMS) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and

Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesdayβs Pre-Market Session
U.S. stock futures rise on Tuesday, but Powell Industries Inc shares fall 13.4% after reporting lower-than-expected earnings and sales.
Fresenius Medical Care Affirms FY2026 Sales Guidance of $23.764B vs $22.940B Est
Fresenius Medical Care (NYSE:FMS) affirms FY2026 sales outlook from $23.764 billion to $23.764 billion vs $22.940 billion estimate.